- Record second quarter 2022 consolidated revenue of $30.5 million up 37% from the same year ago period.
- Adjusted EPS of $(0.22), 52% improvement versus the prior year, 12% sequentially.
- Remain on track to deliver consolidated Adjusted EBITDA profitability by fourth quarter 2022.
- Consolidated Adjusted EBITDA loss was reduced to below $1 million in the month of June.
- LifeMD published a second quarter Supplemental Investor Highlights Presentation, available on the Company’s Investor Relations site, ir.lifemd.com or via direct download at https://ir.lifemd.com/q2.
NEW YORK, Aug. 11, 2022 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ: LFMD), a leading direct-to-patient telehealth company, reported results for the second quarter ended June 30, 2022. All figure comparisons are to the same year-ago quarter unless otherwise noted. Management will host a conference call today, August 11, 2022, at 4:30 p.m. Eastern time to discuss the results.
Q2 2022 Financial Highlights
- Record revenue of $30.5 million, up 37%
- Record Gross Margins of 85%, up from 82% in the same year-ago period. Gross profit totaled $25.8 million
- 93% of revenue generated by subscriptions, 71% of active subscribers on multi-month subscription terms up from 61% in the same year-ago period
- $11.7 million of cash as of June 30, 2022 and no debt
- Adjusted EBITDA loss reduced to below $1 million in the month of June with continued improvements expected
- Adjusted EPS $(0.22), up 52% and a 12% sequential improvement versus the prior quarter (see definition of this non-GAAP financial measure and reconciliation to GAAP, below)
Q2 and Recent Operational Highlights
- Continued leverage of Selling and Marketing expenses, with second quarter expenses as a percentage of revenue reducing to 72%, a 300-basis point improvement versus the prior quarter and a 2,800-basis point improvement versus the same year-ago period.
- Telehealth active subscribers increased 53% to approximately 168,000.
- Increased blended Over-the-Counter (OTC) and Prescription (Rx) 1-year Lifetime Value to Customer Acquisition Costs (LTV-CAC) by 8% year-over-year.
- Made significant progress in the WorkSimpli divestiture process with strong buyer interest. The Company expects to close a transaction by fourth quarter 2022.
- Continued diversification of our core telehealth business with the launch of topical pain management, sleep, OTC skincare and new Virtual Primary Care (VPC) offerings. VPC experienced a 1,500% increase in patient subscribers versus the prior quarter. In the second quarter 2022, non-erectile dysfunction offerings combined for over 38% of new patient acquisitions, up from 22% in the year-ago period.
Key Performance Metrics | ||||||||||
($ in 000s) | Three Months Ended June 30 | Y-o-Y | ||||||||
Key Performance Metrics | 2022 | 2021 | % Growth | |||||||
Revenue | ||||||||||
Telehealth | $ | 22,268 | $ | 15,799 | 41 | % | ||||
WorkSimpli | $ | 8,191 | $ | 6,514 | 26 | % | ||||
Total Revenue | $ | 30,459 | $ | 22,313 | 37 | % | ||||
Subscription Revenue as % of Total | 93 | % | 93 | % | 0 | % | ||||
Telehealth Volume | ||||||||||
Total Telehealth Orders | 255,176 | 195,755 | 30 | % | ||||||
Total Active Subscribers | 168,024 | 109,737 | 53 | % | ||||||
WorkSimpli | ||||||||||
Active Subscribers | 127,304 | 99,576 | 28 | % | ||||||
Management Commentary
“During the second quarter 2022, LifeMD made significant progress against several of our most important strategic initiatives. These include driving our Adjusted EBITDA loss under $1 million in the month of June, beginning to scale Virtual Primary Care, generating a substantial increase in new patient volumes from recently launched telehealth indications and driving an 8% year-over-year improvement in our first year LTV-CAC ratio. In addition, during the quarter we made substantial progress on the divestiture of our non-core WorkSimpli business and remain confident that we can execute a transaction by year end. We highlighted many of these achievements and others in our second quarter Supplemental Investor Highlights Presentation made available after market close on the LifeMD Investor Relations site,” said Justin Schreiber, Chairman & CEO of LifeMD. “While we expect these achievements to position us for long-term profitable growth and shareholder value creation, we anticipate moderated sequential growth over the next two quarters in our core telehealth business as we transition more of our revenue to longer-term subscriptions with stronger unit economics and continue to scale our newly launched virtual primary care business. Importantly, executing upon these strategic initiatives is helping LifeMD transition from a rapidly scaling direct-to-patient telehealth products provider to a rapidly scaling, profitable and differentiated telehealth services company.”
LifeMD CFO Marc Benathen, commented: “As noted in our second quarter Supplemental Investor Highlights Presentation available on our Investor Relations site, most of our Q2 loss was concentrated within the month of April. During the quarter, we made significant progress toward maximizing our unit economics through improved returns on our marketing investment and successfully reduced our Adjusted EBITDA loss to less than $1 million in June. During the quarter, we also made considerable progress in the process to divest our non-core subsidiary, WorkSimpli, and remain confident that we will be able close a transaction before the end of this year. Given our significant focus on continuing to diversify our telehealth revenue by investing in and growing newly launched indications, scaling Virtual Primary Care and driving longer-term subscriptions with more spaced-out re-billings, we expect sequential revenue growth for the next two quarters in our telehealth business to be more moderated. We expect to emerge from this period well-positioned to drive more accelerated top and bottom-line growth as a leading, differentiated direct-to-patient telehealth company. As such, while we reiterate our previous Adjusted EBITDA profitability guidance, we are revising our consolidated Revenue guidance to $122 to $128 million for 2022.”
Q2 2022 Financial Summary
- Revenue for the quarter ended June 30, 2022 increased 37% to $30.5 million from $22.3 million in 2021. The increase in revenues was attributable to a 41% increase in telehealth revenue and a 26% increase in WorkSimpli revenue versus the year-ago period. Following the execution of several key growth initiatives in the preceding quarters, WorkSimpli revenue increased 27% sequentially to a record $8.2 million.
- Gross profit increased by 42% to $25.8 million, compared to $18.2 million in the prior year. Gross margins reached a record 85% for the second quarter ended June 30, 2022.
- Net loss attributable to common stockholders for 2022 was $13.8 million or $(0.45) per share, as compared to a net loss attributable to common stockholders of $16.8 million or $(0.64) per share in the prior year.
- Adjusted EBITDA, a non-GAAP financial measure, totaled a loss of $6.9 million, an improvement of 43% versus the same year-ago period. (see definition of this non-GAAP financial measure and reconciliation to GAAP, below).
- Adjusted EPS, a non-GAAP financial measure, totaled a loss of $(0.22) per share, compared to an adjusted EPS loss of $(0.46) in the same year-ago period. Adjusted EPS improved 12% sequentially versus the prior quarter (see definition of this non-GAAP financial measure and reconciliation to GAAP, below).
- Cash totaled $11.7 million as of June 30, 2022.
Financial Guidance
For the Third Quarter 2022, the Company expects:
- Consolidated Revenue to total between $32 million and $33 million
- Consolidated Adjusted EBITDA between $(1.5) million and $(2.5) million
For the Full Year 2022, the Company expects:
- Consolidated Revenue to total between $122 million and $128 million
- Consolidated Adjusted EBITDA between $(14) million and $(20) million
The Company remains on track to achieve consolidated Adjusted EBITDA profitability by the fourth quarter of 2022.
Conference Call
LifeMD’s management will host a conference call today, August 11, 2022 at 4:30 pm Eastern Time to discuss the company’s financial results and outlook, followed by a question-and-answer period. Details for the call are as follows:
Toll-free dial-in number: | 1-800-263-0877 |
International dial-in number: | 1-720-543-0197 |
Conference ID: | 9480029 |
Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1560537&tp_key=0592b1380e |
The conference call will be webcast live and available for replay via a link provided in the Investors section of the company’s website at lifemd.com. Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.
Listeners are encouraged to review the Company's periodic reports filed with the U.S. Securities and Exchange Commission, including the discussion of risk factors, historical results of operations and financial condition as provided in these reports.
About LifeMD
LifeMD is a 50-state direct-to-patient telehealth company with a portfolio of brands that offer virtual primary care, diagnostics, and specialized treatment for men’s and women’s health, allergy & asthma, and dermatological conditions. By leveraging its proprietary technology platform, 50-state affiliated medical group, and nationwide mail-order pharmacy network, LifeMD is increasing access to top-notch healthcare that is affordable to anyone. To learn more, go to LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Company Contact
LifeMD, Inc.
Marc Benathen, CFO
marc@lifemd.com
Tables to Follow
LIFEMD, INC. | ||||||||
CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
(Unaudited) | ||||||||
June 30, 2022 | December 31, 2021 | |||||||
ASSETS | ||||||||
Current Assets | ||||||||
Cash | $ | 11,717,302 | $ | 41,328,039 | ||||
Accounts receivable, net | 2,513,627 | 980,055 | ||||||
Product deposit | 440,841 | 203,556 | ||||||
Inventory, net | 2,965,242 | 1,616,600 | ||||||
Other current assets | 873,205 | 793,190 | ||||||
Total Current Assets | 18,510,217 | 44,921,440 | ||||||
Non-current Assets | ||||||||
Equipment, net | 555,777 | 233,805 | ||||||
Right of use asset, net | 1,462,086 | 1,752,448 | ||||||
Capitalized software, net | 6,542,691 | 2,995,789 | ||||||
Goodwill and intangible assets, net | 10,898,710 | 19,761 | ||||||
Total Non-current Assets | 19,459,264 | 5,001,803 | ||||||
Total Assets | $ | 37,969,481 | $ | 49,923,243 | ||||
LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities | ||||||||
Accounts payable | $ | 11,938,937 | $ | 9,059,214 | ||||
Accrued expenses | 11,233,309 | 11,595,605 | ||||||
Notes payable, net | - | 63,400 | ||||||
Current operating lease liabilities | 704,283 | 607,490 | ||||||
Deferred revenue | 1,992,502 | 1,499,880 | ||||||
Total Current Liabilities | 25,869,031 | 22,825,589 | ||||||
Long-term Liabilities | ||||||||
Noncurrent operating lease liabilities | 871,300 | 1,178,544 | ||||||
Contingent consideration | 2,934,750 | 100,000 | ||||||
Purchase price payable | 1,480,008 | - | ||||||
Total Liabilities | 31,155,089 | 24,104,133 | ||||||
Commitments and Contingencies | ||||||||
Mezzanine Equity | ||||||||
Preferred Stock, $0.0001 par value; 5,000,000 shares authorized | ||||||||
Series B Preferred Stock, $0.0001 par value; 5,000 shares authorized, 3,500 and 3,500 shares issued and outstanding, liquidation value approximately, $1,239 and $1,175 per share as of June 30, 2022 and December 31, 2021, respectively | 4,336,452 | 4,110,822 | ||||||
Stockholders’ Equity | ||||||||
Series A Preferred Stock, $0.0001 par value; 1,610,000 shares authorized, 1,400,000 shares issued and outstanding, liquidation value approximately $26.72 and $25.62 per share as of June 30, 2022 and December 31, 2021, respectively | 140 | 140 | ||||||
Common Stock, $0.01 par value; 100,000,000 shares authorized, 30,989,869 and 30,704,434 shares issued, 30,886,829 and 30,601,394 outstanding as of June 30, 2022 and December 31, 2021, respectively | 309,899 | 307,045 | ||||||
Additional paid-in capital | 173,157,467 | 164,517,634 | ||||||
Accumulated deficit | (169,792,847 | ) | (141,921,085 | ) | ||||
Treasury stock, 103,040 and 103,040 shares, at cost | (163,701 | ) | (163,701 | ) | ||||
Total LifeMD, Inc. Stockholders’ Equity | 3,510,958 | 22,740,033 | ||||||
Non-controlling interest | (1,033,018 | ) | (1,031,745 | ) | ||||
Total Stockholders’ Equity | 2,477,940 | 21,708,288 | ||||||
Total Liabilities, Mezzanine Equity and Stockholders’ Equity | $ | 37,969,481 | $ | 49,923,243 | ||||
LIFEMD, INC. | ||||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
(Unaudited) | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Revenues | ||||||||||||||||
Telehealth revenue, net | $ | 22,267,963 | $ | 15,799,610 | $ | 44,866,024 | $ | 29,082,925 | ||||||||
WorkSimpli revenue, net | 8,190,535 | 6,514,001 | 14,635,311 | 11,428,798 | ||||||||||||
Total revenues, net | 30,458,498 | 22,313,611 | 59,501,335 | 40,511,723 | ||||||||||||
Cost of revenues | ||||||||||||||||
Cost of telehealth revenue | 4,453,126 | 4,021,005 | 9,539,194 | 7,144,030 | ||||||||||||
Cost of WorkSimpli revenue | 182,185 | 99,215 | 344,292 | 187,247 | ||||||||||||
Total cost of revenues | 4,635,311 | 4,120,220 | 9,883,486 | 7,331,277 | ||||||||||||
Gross profit | 25,823,187 | 18,193,391 | 49,617,849 | 33,180,446 | ||||||||||||
Expenses | ||||||||||||||||
Selling and marketing expenses | 21,817,966 | 22,392,179 | 43,727,791 | 41,078,880 | ||||||||||||
General and administrative expenses | 13,250,669 | 10,523,071 | 25,553,147 | 17,498,642 | ||||||||||||
Other operating expenses | 1,951,244 | 809,066 | 3,278,978 | 1,445,853 | ||||||||||||
Customer service expenses | 1,006,363 | 473,235 | 1,939,670 | 768,512 | ||||||||||||
Development costs | 701,070 | 122,603 | 1,129,403 | 433,659 | ||||||||||||
Goodwill impairment charge | 2,735,000 | - | 2,735,000 | - | ||||||||||||
Total expenses | 41,462,312 | 34,320,154 | 78,363,989 | 61,225,546 | ||||||||||||
Operating loss | (15,639,125 | ) | (16,126,763 | ) | (28,746,140 | ) | (28,045,100 | ) | ||||||||
Interest expense, net | (132,236 | ) | (901,910 | ) | (300,170 | ) | (1,041,373 | ) | ||||||||
Change in fair value of contingent consideration | 2,735,000 | - | 2,735,000 | - | ||||||||||||
Gain on debt forgiveness | 63,400 | - | 63,400 | 184,914 | ||||||||||||
Net loss | (12,972,961 | ) | (17,028,673 | ) | (26,247,910 | ) | (28,901,559 | ) | ||||||||
Net income (loss) attributable to noncontrolling interests | 46,001 | (197,973 | ) | 70,727 | (468,476 | ) | ||||||||||
Net loss attributable to LifeMD, Inc. | (13,018,962 | ) | (16,830,700 | ) | (26,318,637 | ) | (28,433,083 | ) | ||||||||
Preferred stock dividends | (776,562 | ) | - | (1,553,125 | ) | - | ||||||||||
Net loss attributable to LifeMD, Inc. common stockholders | $ | (13,795,524 | ) | $ | (16,830,700 | ) | $ | (27,871,762 | ) | $ | (28,433,083 | ) | ||||
Basic loss per share attributable to LifeMD, Inc. common stockholders | $ | (0.45 | ) | $ | (0.64 | ) | $ | (0.90 | ) | $ | (1.12 | ) | ||||
Diluted loss per share attributable to LifeMD, Inc. common stockholders | $ | (0.45 | ) | $ | (0.64 | ) | $ | (0.90 | ) | $ | (1.12 | ) | ||||
Weighted average number of common shares outstanding: | ||||||||||||||||
Basic | 30,907,505 | 26,289,678 | 30,880,417 | 25,381,530 | ||||||||||||
Diluted | 30,907,505 | 26,289,678 | 30,880,417 | 25,381,530 | ||||||||||||
LIFEMD, INC. | |||||||||||||||
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | |||||||||||||||
(Unaudited) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
CASH FLOWS FROM OPERATING ACTIVITIES | |||||||||||||||
Net loss | $ | (12,972,961 | ) | $ | (17,028,673 | ) | $ | (26,247,910 | ) | $ | (28,901,559 | ) | |||
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||||||||||
Amortization of debt discount | - | 522,559 | - | 522,559 | |||||||||||
Amortization of capitalized software | 592,214 | 39,413 | 976,026 | 63,864 | |||||||||||
Amortization of intangibles | 226,893 | 255,937 | 341,287 | 339,840 | |||||||||||
Accretion of consideration payable | 135,368 | 135,368 | |||||||||||||
Depreciation of fixed assets | 40,770 | - | 73,247 | - | |||||||||||
Gain on forgiveness of debt | (63,400 | ) | - | (63,400 | ) | (184,914 | ) | ||||||||
Change in fair value of contingent consideration | (2,735,000 | ) | - | (2,735,000 | ) | - | |||||||||
Goodwill impairment charge | 2,735,000 | - | 2,735,000 | - | |||||||||||
Operating lease payments | 171,838 | 24,589 | 290,362 | 49,178 | |||||||||||
Stock compensation expense | 4,041,006 | 2,547,300 | 8,513,787 | 4,873,075 | |||||||||||
- | - | ||||||||||||||
Changes in Assets and Liabilities | - | - | |||||||||||||
Accounts receivable | (717,125 | ) | (381,152 | ) | (1,533,572 | ) | (1,084,174 | ) | |||||||
Product deposit | 174,452 | (91,521 | ) | (237,285 | ) | (574,999 | ) | ||||||||
Inventory | (1,725,208 | ) | 60,264 | (1,341,474 | ) | (349,859 | ) | ||||||||
Other current assets | (30,216 | ) | (342,432 | ) | (80,015 | ) | (292,357 | ) | |||||||
Change in operating lease liability | (164,950 | ) | (22,731 | ) | (210,451 | ) | (44,653 | ) | |||||||
Deferred revenue | 203,947 | 42,629 | 492,622 | 465,058 | |||||||||||
Accounts payable | 376,345 | 1,131,477 | 2,853,811 | 1,256,110 | |||||||||||
Accrued expenses | (387,938 | ) | 2,588,811 | (2,152,511 | ) | 4,022,422 | |||||||||
Net cash used in operating activities | (10,098,965 | ) | (10,653,530 | ) | (18,190,108 | ) | (19,840,409 | ) | |||||||
CASH FLOWS FROM INVESTING ACTIVITIES | |||||||||||||||
Cash paid for capitalized software costs | (2,424,785 | ) | (903,487 | ) | (4,522,928 | ) | (952,347 | ) | |||||||
Purchase of equipment | (90,180 | ) | (18,116 | ) | (357,331 | ) | (18,116 | ) | |||||||
Purchase of intangible assets | - | - | (4,000,500 | ) | - | ||||||||||
Acquisition of business, net of cash acquired | - | - | (1,012,395 | ) | - | ||||||||||
Net cash used in investing activities | (2,514,965 | ) | (921,603 | ) | (9,893,154 | ) | (970,463 | ) | |||||||
CASH FLOWS FROM FINANCING ACTIVITIES | |||||||||||||||
Cash proceeds from private placement offering, net | - | - | - | 13,495,270 | |||||||||||
Proceeds from issuance of debt instruments | - | 15,000,000 | - | 15,000,000 | |||||||||||
Cash proceeds from exercise of options | 90,400 | 742,750 | 90,400 | 766,750 | |||||||||||
Cash proceeds from exercise of warrants | - | 311,999 | 38,500 | 311,999 | |||||||||||
Preferred stock dividends | (776,562 | ) | - | (1,553,125 | ) | - | |||||||||
Proceeds from notes payable | - | 363,965 | - | 963,965 | |||||||||||
Repayment of notes payable | - | (600,000 | ) | - | (1,119,950 | ) | |||||||||
Contingent consideration payment for ResumeBuild | (31,250 | ) | (31,250 | ) | |||||||||||
Purchase of membership interest of WorkSimpli | - | (200,000 | ) | - | (300,000 | ) | |||||||||
Distributions to non-controlling interest | (36,000 | ) | (36,000 | ) | (72,000 | ) | (72,000 | ) | |||||||
Net cash (used in) provided by financing activities | (753,412 | ) | 15,582,714 | (1,527,475 | ) | 29,046,034 | |||||||||
Net (decrease) increase in cash | (13,367,342 | ) | (4,007,581 | ) | (29,610,737 | ) | 8,235,162 | ||||||||
Cash at beginning of period | 25,084,644 | 13,406,656 | 41,328,039 | 9,179,075 | |||||||||||
Cash at end of period | $ | 11,717,302 | $ | 17,414,237 | $ | 11,717,302 | $ | 17,414,237 | |||||||
Cash paid for interest | |||||||||||||||
Cash paid during the period for interest | $ | - | $ | 125,912 | $ | - | $ | 143,183 | |||||||
Non-cash investing and financing activities: | |||||||||||||||
Cashless exercise of warrants | $ | - | $ | - | $ | - | $ | - | |||||||
Cashless exercise of options | $ | - | $ | - | $ | 255 | $ | - | |||||||
Consideration payable for Cleared acquisition | $ | - | $ | - | $ | 8,079,367 | $ | - | |||||||
Consideration payable for ResumeBuild acquisition | $ | - | $ | - | $ | 500,000 | $ | - | |||||||
Warrants issued for debt instruments | $ | - | $ | 6,270,710 | $ | - | $ | 6,270,710 | |||||||
Principal of Paycheck Protection Program loans forgiven | $ | 63,400 | $ | - | $ | 63,400 | $ | 184,914 | |||||||
Additional purchase of membership interest in WorkSimpli issued in performance options | $ | - | $ | - | $ | - | $ | 144,002 | |||||||
About the Use of Non-GAAP Financial Measures:
To supplement our financial information presented in accordance with GAAP, we use Adjusted EBITDA and Adjusted EPS as non-GAAP financial measures to clarify and enhance an understanding of past performance. We believe that the presentation of these financial measures enhances an investor’s understanding of our financial performance. We further believe that these financial measures are useful financial metrics to assess our operating performance from period-to-period by excluding certain items that we believe are not representative of our core business. We use certain financial measures for business planning purposes and in measuring our performance relative to that of our competitors.
Adjusted EBITDA is defined as income (loss) attributable to common shareholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, inventory valuation, litigation costs, gain on debt forgiveness, preferred stock dividends, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of Adjusted EBITDA to Net loss attributable to common shareholders, its most directly comparable GAAP financial measure.
Adjusted EPS is defined as the diluted net loss attributable to LifeMD, Inc common shareholders before interest, taxes, depreciation, amortization, accretion, financing transaction expense, inventory valuation, litigation costs, preferred stock dividends, acquisition costs, severance expenses and stock-based compensation expense. We have provided below a reconciliation of Adjusted EPS to Diluted loss per share attributable to LifeMD, Inc common shareholders, its most directly comparable GAAP financial measure.
We believe the above financial measures are commonly used by investors to evaluate our performance and that of our competitors. However, our use of the terms Adjusted EBITDA and Adjusted EPS may vary from that of others in our industry. Adjusted EBITDA and Adjusted EPS should not be considered as an alternative to net loss before taxes, net loss per share, operating loss or any other performance measures derived in accordance with GAAP as measures of performance.
Reconciliation of GAAP Net Loss to Adjusted EBITDA | |||||||||||||||
(in whole numbers, unaudited) | |||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||||
2022 | 2021 | 2022 | 2021 | ||||||||||||
Net loss attributable to common shareholders | $ | (13,795,524 | ) | $ | (16,830,700 | ) | $ | (27,871,762 | ) | $ | (28,433,083 | ) | |||
Interest expense (excluding debt discount and acceleration of debt) | 18,798 | 798,472 | 74,540 | 815,743 | |||||||||||
Depreciation, amortization and accretion expense | 995,245 | - | 1,525,928 | 403,704 | |||||||||||
Amortization of debt discount | - | - | - | 522,559 | |||||||||||
Gain on debt forgiveness | (63,400 | ) | - | (63,400 | ) | (184,914 | ) | ||||||||
Financing transactions expense | - | 946,411 | 152,015 | 1,072,390 | |||||||||||
Litigation costs | 655,494 | 215,125 | 704,359 | 215,125 | |||||||||||
Inventory valuation adjustment | 13,708 | - | 230,661 | - | |||||||||||
Severance costs | 77,241 | - | 179,090 | - | |||||||||||
Acquisitions expenses | 240,153 | - | 265,153 | - | |||||||||||
Accrued interest on Series B Convertible Preferred Stock | 113,438 | 103,438 | 225,630 | 225,630 | |||||||||||
Preferred dividends | 776,562 | - | 1,553,125 | - | |||||||||||
Stock-based compensation expense | 4,041,006 | 2,547,300 | 8,513,787 | 4,873,075 | |||||||||||
Adjusted EBITDA | $ | (6,927,279 | ) | $ | (12,219,954 | ) | $ | (14,510,874 | ) | $ | (20,489,771 | ) | |||
Reconciliation of GAAP Diluted Loss per Share Attributable to Common Shareholders to Adjusted EPS | ||||||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
2022 | 2021 | 2022 | 2021 | |||||||||||||
Diluted loss per share attributable to LifeMD, Inc. common shareholders | $ | (0.45 | ) | $ | (0.64 | ) | $ | (0.91 | ) | $ | (1.12 | ) | ||||
Adjustments to Reconcile GAAP Diluted Loss Per Share to Adjusted EPS | ||||||||||||||||
Interest expense (excluding debt discount and acceleration of debt) | - | 0.03 | - | 0.03 | ||||||||||||
Depreciation, amortization and accretion expense | 0.03 | - | 0.05 | 0.02 | ||||||||||||
Amortization of debt discount | - | - | - | 0.02 | ||||||||||||
Gain on debt forgiveness | - | - | - | (0.01 | ) | |||||||||||
Financing transactions expense | - | 0.04 | - | 0.04 | ||||||||||||
Litigation costs | 0.02 | 0.01 | 0.02 | 0.01 | ||||||||||||
Inventory valuation adjustment | - | - | 0.01 | - | ||||||||||||
Severance costs | - | - | 0.01 | - | ||||||||||||
Acquisitions expenses | 0.01 | - | 0.01 | - | ||||||||||||
Accrued interest on Series B Convertible Preferred Stock | 0.01 | - | 0.01 | 0.01 | ||||||||||||
Preferred dividends | 0.03 | - | 0.05 | - | ||||||||||||
Stock-based compensation expense | 0.13 | 0.10 | 0.28 | 0.19 | ||||||||||||
Adjusted EPS | $ | (0.22 | ) | $ | (0.46 | ) | $ | (0.47 | ) | $ | (0.81 | ) | ||||